(NVS) Novartis - Ratings and Ratios
Cardiovascular,Oncology,Immunology,Neuroscience,Hematology
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.2% |
| Value at Risk 5%th | 33.9% |
| Relative Tail Risk | -2.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.94 |
| Alpha | 19.07 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.593 |
| Beta | 0.218 |
| Beta Downside | 0.238 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.95% |
| Mean DD | 4.74% |
| Median DD | 3.90% |
Description: NVS Novartis September 24, 2025
Novartis AG (NYSE: NVS) is a Swiss-based, globally integrated pharmaceutical company that researches, develops, manufactures, distributes, markets and sells prescription medicines across a broad therapeutic spectrum.
Key product highlights include Entresto for heart-failure with reduced ejection fraction, Cosentyx for psoriasis and related inflammatory diseases, Kisqali (CDK4/6 inhibitor) for breast cancer, Promacta/Revolade for immune-mediated thrombocytopenia, the Tafinlar + Mekinist combo for targeted oncology, and Jakavi for myelofibrosis and related disorders. Additional assets span Tasigna for chronic myeloid leukemia, Xolair for allergic asthma, Ilaris for autoinflammatory conditions, Pluvicto for metastatic castration-resistant prostate cancer, Sandostatin formulations for neuroendocrine tumors, Zolgensma for spinal muscular atrophy, Lucentis for retinal disease, Leqvio (inclisiran) for LDL-cholesterol reduction, Lutathera for neuroendocrine tumors, Scemblix and Fabhalta among others.
The company’s therapeutic focus is concentrated in cardiovascular-renal-metabolic, immunology, neuroscience, oncology and hematology, reflecting both the highest unmet-need areas and the segments with the strongest pipeline growth potential.
Novartis maintains a strategic partnership with Alnylam Pharmaceuticals to co-develop, manufacture and commercialize Leqvio, leveraging RNA-interference technology to expand its lipid-lowering franchise.
Financially, Novartis reported FY 2023 revenue of $51.6 billion, with an operating margin of 23 % and R&D expenditure of $9.6 billion, underscoring its commitment to pipeline renewal. The dividend yield hovered around 3.5 % and the company returned $8.0 billion to shareholders via buybacks and dividends, indicating a mature cash-generation profile.
Sector-level drivers that will likely shape Novartis’ outlook include an aging global population driving demand for chronic-disease therapies, continued pricing pressure in the United States, and accelerating adoption of advanced modalities such as gene-therapy and RNA-based medicines, which are reshaping competitive dynamics.
For a deeper quantitative assessment of Novartis’ valuation metrics, you may find the ValueRay platform useful.
NVS Stock Overview
| Market Cap in USD | 244,281m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1991-11-18 |
| Return 12m vs S&P 500 | 11.7% |
| Analyst Rating | 2.85 of 5 |
NVS Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.21% |
| Yield on Cost 5y | 5.92% |
| Yield CAGR 5y | 5.30% |
| Payout Consistency | 96.4% |
| Payout Ratio | 44.7% |
NVS Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 19.21% |
| CAGR/Max DD Calmar Ratio | 0.96 |
| CAGR/Mean DD Pain Ratio | 4.06 |
| Current Volume | 2416k |
| Average Volume | 1657.1k |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (14.39b TTM) > 0 and > 6% of Revenue (6% = 3.38b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 3.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.74% (prev 6.27%; Δ -13.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 21.07b > Net Income 14.39b (YES >=105%, WARN >=100%) |
| Net Debt (22.47b) to EBITDA (22.94b) ratio: 0.98 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.94b) change vs 12m ago -4.29% (target <= -2.0% for YES) |
| Gross Margin 76.21% (prev 74.92%; Δ 1.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.48% (prev 48.24%; Δ 5.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.68 (EBITDA TTM 22.94b / Interest Expense TTM 1.12b) >= 6 (WARN >= 3) |
Altman Z'' 2.95
| (A) -0.04 = (Total Current Assets 28.20b - Total Current Liabilities 32.00b) / Total Assets 107.29b |
| (B) 0.41 = Retained Earnings (Balance) 43.51b / Total Assets 107.29b |
| (C) 0.17 = EBIT TTM 17.53b / Avg Total Assets 105.41b |
| (D) 0.71 = Book Value of Equity 44.37b / Total Liabilities 62.54b |
| Total Rating: 2.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 94.26
| 1. Piotroski 9.0pt |
| 2. FCF Yield 6.40% |
| 3. FCF Margin 30.26% |
| 4. Debt/Equity 0.72 |
| 5. Debt/Ebitda 0.98 |
| 6. ROIC - WACC (= 16.64)% |
| 7. RoE 34.12% |
| 8. Rev. Trend 81.09% |
| 9. EPS Trend 88.76% |
What is the price of NVS shares?
Over the past week, the price has changed by -5.72%, over one month by -5.64%, over three months by -2.27% and over the past year by +24.98%.
Is NVS a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 2
What are the forecasts/targets for the NVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 131.3 | 5.6% |
| Analysts Target Price | 131.3 | 5.6% |
| ValueRay Target Price | 151.6 | 21.9% |
NVS Fundamental Data Overview November 21, 2025
P/E Trailing = 17.4159
P/E Forward = 13.986
P/S = 4.3334
P/B = 5.5408
P/EG = 1.0435
Beta = 0.439
Revenue TTM = 56.37b USD
EBIT TTM = 17.53b USD
EBITDA TTM = 22.94b USD
Long Term Debt = 22.60b USD (from longTermDebt, last quarter)
Short Term Debt = 7.78b USD (from shortTermDebt, last quarter)
Debt = 32.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.47b USD (from netDebt column, last quarter)
Enterprise Value = 266.55b USD (244.28b + Debt 32.02b - CCE 9.75b)
Interest Coverage Ratio = 15.68 (Ebit TTM 17.53b / Interest Expense TTM 1.12b)
FCF Yield = 6.40% (FCF TTM 17.06b / Enterprise Value 266.55b)
FCF Margin = 30.26% (FCF TTM 17.06b / Revenue TTM 56.37b)
Net Margin = 25.53% (Net Income TTM 14.39b / Revenue TTM 56.37b)
Gross Margin = 76.21% ((Revenue TTM 56.37b - Cost of Revenue TTM 13.41b) / Revenue TTM)
Gross Margin QoQ = 75.35% (prev 77.61%)
Tobins Q-Ratio = 2.48 (Enterprise Value 266.55b / Total Assets 107.29b)
Interest Expense / Debt = 0.88% (Interest Expense 281.0m / Debt 32.02b)
Taxrate = 6.34% (266.0m / 4.20b)
NOPAT = 16.42b (EBIT 17.53b * (1 - 6.34%))
Current Ratio = 0.88 (Total Current Assets 28.20b / Total Current Liabilities 32.00b)
Debt / Equity = 0.72 (Debt 32.02b / totalStockholderEquity, last quarter 44.33b)
Debt / EBITDA = 0.98 (Net Debt 22.47b / EBITDA 22.94b)
Debt / FCF = 1.32 (Net Debt 22.47b / FCF TTM 17.06b)
Total Stockholder Equity = 42.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.42% (Net Income 14.39b / Total Assets 107.29b)
RoE = 34.12% (Net Income TTM 14.39b / Total Stockholder Equity 42.18b)
RoCE = 27.07% (EBIT 17.53b / Capital Employed (Equity 42.18b + L.T.Debt 22.60b))
RoIC = 22.77% (NOPAT 16.42b / Invested Capital 72.14b)
WACC = 6.12% (E(244.28b)/V(276.30b) * Re(6.82%) + D(32.02b)/V(276.30b) * Rd(0.88%) * (1-Tc(0.06)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 79.80% ; FCFE base≈15.24b ; Y1≈17.00b ; Y5≈22.45b
Fair Price DCF = 203.0 (DCF Value 389.58b / Shares Outstanding 1.92b; 5y FCF grow 13.36% → 3.0% )
EPS Correlation: 88.76 | EPS CAGR: 15.33% | SUE: -0.57 | # QB: 0
Revenue Correlation: 81.09 | Revenue CAGR: 3.43% | SUE: 1.00 | # QB: 2
Additional Sources for NVS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle